JPRN-jRCTs031230645招募中3 期
JCOG2215: A randomized controlled phase III trial comparing endoscopic balloon dilation alone versus endoscopic balloon dilation with local triamcinolone injection for esophageal stricture after endoscopic submucosal dissection for esophageal cancer - ACCELERATE trial
Yano Tomonori0 个研究点目标入组 260 人开始时间: 2024年2月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1st inclusion criteria
- •(1) Meet all the following about endoscopic submucosal dissection (ESD) for esophageal cancer:
- •(a) Meet either of the following.
- •(i) For a single lesion:
- •non-circumferential lesion measuring 8 cm or less in the longitudinal axis, or circumferential lesion measuring 5 cm or less in the longitudinal axis
- •(ii) For synchronous multiple lesions:
- •all lesions are non-circumferential and the entire lesion has a longitudinal axis of 8 cm or less, or either lesion is circumferential and the entire lesion has a longitudinal axis of 5 cm or less.
- •(b) En bloc resection and no macroscopic residual tumor.
- •(c) Histologically proven squamous cell carcinoma or basaloid carcinoma.
- •(d) Histologically diagnosed pT1a, Ly0, V0 and pVM0.
- •(2) No rule on whether and how to prevent post-ESD stricture.
- •(3) Dysphagia score >=1.
- •(4) Meet either of the following criteria in terms of endoscopic balloon dilation (EBD) for post-ESD stricture
- •(a)No prior dilation therapy
- •(b) Only one EBD alone and the period between that EBD and the secondary enrollment can be at least 14 days (the same day of the week two weeks later is acceptable).
- •(5) Age >=18
- •(6) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- •(7) No prior treatment for esophageal cancer other than endoscopic resection
- •(8) No history of metachronous multiple esophageal cancers unless all of the following are met.
- •(a) Prior endoscopic resection
- •(b) No macroscopic residual tumor.
- •(c) Histologically proven squamous cell carcinoma or basaloid carcinoma.
- •(d) Histologically diagnosed pT1a, Ly0, V0 and pVM0.
- •(e) No post esophageal ESD stricture with scarring confirmed by a surveillance endoscopy, or a resolved post ESD esophageal stricture confirmed by a follow up endoscopy 4 weeks or later after dilation therapies.
- •(9) No history of head and neck cancer unless all of the following are met.
- •(a) No evidence of recurrence.
- •(b) No post ESD stricture with scarring confirmed by a surveillance endoscopy, or a resolved post ESD esophageal stricture confirmed by a follow up endoscopy 4 weeks or later after dilation therapies
- •(10) No prior chemotherapy for any cancer within 28 days before registration, and no plan of chemotherapy within 24 weeks after registration.
- •(11) No prior radiotherapy to the neck, chest wall, lung, or mediastinum
- •(12) Sufficient organ function
- •(a) White blood cell count >=2,000/mm3 and <=12,000/mm3.
- •(b) Hemoglobin >=8.0 g/dL.
- •(c) Platelet >=100,000/mm3.
- •(d) Total bilirubin <=2.0 mg/dL.
- •(e) Aspartate aminotransferase <=150 U/L.
- •(f) Alanine aminotransferase <=150 U/L.
- •(g) Creatinine <=2.0 mg/dL.
- •(13) Written informed consent
- •2nd inclusion criteria
- •(1) Within 28 days from the first registration.
- •(2) No treatment for post-ESD stricture has been done since the first registration.
- •(3) If a patient has received a single dose of EBD for post-ESD esophageal stricture before the first registration, it has been more than 14 days since the EBD.
- •(4) All of the following are met with the latest follow-up endoscopy performed within 28 days before the second registration.
- •(a) There is a post-ESD stricture in the thoracic esophagus that the endoscope (9.8-9.9 mm in diameter) does not pass through. Pinhole stricture which an EBD balloon catheter cannot pass through is ineligible.
- •(b) No stricture in the pharynx and cervical esophagus
- •(c) No ulceration in the post-ESD stricture. Erosion is acceptable.
排除标准
- •(1) Active infection requiring systemic therapy.
- •(2) Body temperature >=38 degrees Celsius.
- •(3) Pregnancy, possible pregnancy, within 28 days after delivery or breastfeeding.
- •(4) Severe psychiatric disease.
- •(5) Receiving continuous systemic steroid or immunosuppressant treatment except steroid for the prevention of stricture after ESD for esophageal cancer.
- •(6) Patients requiring continuous anticoagulant or antiplatelet drug.
- •(7) Poorly controlled hypertension.
- •(8) History of unstable angina within 3 weeks or myocardial infarction within 6 months.
研究者
相似试验
招募中
3 期
JCOG2207: A phase III randomized controlled trial comparing total mesorectal excision and lateral lymph node dissection plus adjuvant chemotherapy with total neoadjuvant therapy followed by total mesorectal excision and selective lateral lymph node dissection for the patients with locoregionally advanced low rectal cancerRectal cancerJPRN-jRCTs031230415OHUE Masayuki420
招募中
3 期
JCOG2206: A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomyEsophageal squamous cell carcinoma with no pathological complete response after neoadjuvant therapyJPRN-jRCTs031230219KITAGAWA Yuko450
招募中
3 期
JCOG1905: A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinomaadvanced renal cell carcinomaJPRN-jRCT1031200071MATSUMOTO Takashi250
招募中
3 期
JCOG2011: A randomized controlled phase III trial for confirming superiority of local radiotherapy added to anti-androgen therapy for prostate cancer patients with high volume metastasis sensitive to hormone therapyhigh volume metastatic prostate cancerJPRN-jRCT1031220676KAMOTO Toshiyuki440
招募中
3 期
JCOG1801: A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancerresectable locally recurrent rectal cancerJPRN-jRCTs031190076Ito Masaaki110